Rubicon Genomics, Inc. to Supply OmniPLEX(R) Technology to Kreatech Diagnostics for Use in Manufacturing REPEAT-FREE(TM) POSEIDON(TM) FISH Probes
Published: Apr 12, 2012
ANN ARBOR, Mich., April 12, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a company developing and commercializing pre-analytical processes to improve the capabilities and performance of DNA and RNA analytical platforms, today announced that it has signed a supply agreement with KREATECH Diagnostics for use of Rubicon's OmniPLEX-D whole genome amplification technology. Under the terms of the agreement, Rubicon will provide proprietary reagents incorporating elements of its OmniPLEX® amplification technology to KREATECH for use in the manufacture of KREATECH's POSEIDON fluorescence in situ hybridization (FISH) probes.
"This new agreement further demonstrates the broad applicability of our suite of pre-analytical amplification technologies for producing superior results in nucleic acid detection and analysis," noted James Koziarz, CEO of Rubicon. "By incorporating key elements of our technology into their manufacturing process, KREATECH is able to enhance the reliability, efficiency and reproducibility of production of their FISH probes. Collaborating with a diverse group of industry leaders is a key part of Rubicon's strategy, and we are very pleased to be working with KREATECH, which offers the broadest commercial portfolio of high quality FISH probes available today."
"KREATECH's POSEIDON REPEAT-FREE technology eliminates repetitive elements in DNA FISH probes and in combination with our unique proprietary labeling technologythe ULS technologydelivers results that have less background, more specificity and a brighter signal," commented Herman Volkers, COO of KREATECH. "Use of Rubicon's proprietary pre-analytical amplification reagents during the production process contributes to achievement of this superior performance; therefore we are pleased to conclude this renewed supply agreement with Rubicon Genomics."
Rubicon's OmniPLEX® family of amplification technologies are designed to deliver sufficient quantities of high quality species-specific or locus-specific RNA or DNA to increase the sensitivity and specificity of analyses of biological samples for biomedical research and clinical medicine. They use proprietary methods to prepare samples for sensitive and accurate PCR, microarray and next-generation sequencing analysis, and provide exceptional consistency, superior performance and proven sensitivity.
Further terms of the agreement were not disclosed.
About Rubicon Genomics
Rubicon Genomics, Inc. is a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for a variety of research and clinical testing applications. The company's core competency is the creation of more efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult clinical samples to facilitate gene-based research, drug development, diagnostics and forensics. Privately held Rubicon is located in Ann Arbor, Michigan. More information can be found at www.rubicongenomics.com.
About KREATECH Diagnostics
KREATECH Diagnostics is a molecular diagnostics company focusing on the development and worldwide commercialization of innovative detection products. KREATECH's product portfolio enables customers to detect genetic aberrations that may lead to cancer or other diseases. KREATECH offers the broadest commercial portfolio of Fluorescent in Situ Hybridization (FISH) probes available in the industry: more than 450 REPEAT-FREE POSEIDON probes. The REPEAT-FREE technology eliminates the use of Cot-1 or blocking DNA, providing less background and a brighter signal which are important features for FISH as a diagnostic and research tool. In addition, KREATECH has a dedicated portfolio of microarray labeling applications using its proprietary non-enzymatic Universal Linkage System (ULS) labeling technology. KREATECH Diagnostics has commercial operations both in Europe and North America. For more information, please visit www.kreatech.com.
Barbara Lindheim or Jennifer Anderson
Chief Executive Officer
GendeLLindheim BioCom Partners
SOURCE Rubicon Genomics, Inc.